GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » EV-to-Revenue

Nectar Lifesciences (LUX:NECLF) EV-to-Revenue : 0.77 (As of Jun. 10, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nectar Lifesciences's enterprise value is $156.9 Mil. Nectar Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $203.1 Mil. Therefore, Nectar Lifesciences's EV-to-Revenue for today is 0.77.

The historical rank and industry rank for Nectar Lifesciences's EV-to-Revenue or its related term are showing as below:

LUX:NECLF' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.07   Med: 0.45   Max: 1.25
Current: 0.78

During the past 13 years, the highest EV-to-Revenue of Nectar Lifesciences was 1.25. The lowest was 0.07. And the median was 0.45.

LUX:NECLF's EV-to-Revenue is ranked better than
84.58% of 1018 companies
in the Drug Manufacturers industry
Industry Median: 2.27 vs LUX:NECLF: 0.78

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-10), Nectar Lifesciences's stock price is $0.376. Nectar Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.90. Therefore, Nectar Lifesciences's PS Ratio for today is 0.42.


Nectar Lifesciences EV-to-Revenue Historical Data

The historical data trend for Nectar Lifesciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences EV-to-Revenue Chart

Nectar Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.84 0.83 0.72 0.76

Nectar Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.30 0.78 0.44 0.76

Competitive Comparison of Nectar Lifesciences's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's EV-to-Revenue falls into.



Nectar Lifesciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nectar Lifesciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=156.872/203.128
=0.77

Nectar Lifesciences's current Enterprise Value is $156.9 Mil.
Nectar Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $203.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nectar Lifesciences  (LUX:NECLF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nectar Lifesciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.376/0.904
=0.42

Nectar Lifesciences's share price for today is $0.376.
Nectar Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.90.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nectar Lifesciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nectar Lifesciences (LUX:NECLF) Business Description

Traded in Other Exchanges
Address
SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines